Novelos Therapeutics, Inc. To Meet FDA In Early December To Review Positive Phase 1/2 Lung Cancer Data

NEWTON, Mass.--(BUSINESS WIRE)--Oct. 24, 2005--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focusing on oxidized glutathione for use in fighting cancer and hepatitis, announced today that the FDA has granted the Company an End-of-Phase 2 meeting, scheduled for December 2, 2005.